VIIBRYD Drug Patent Profile

When do Viibryd patents expire, and when can generic versions of Viibryd launch?

Viibryd is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in VIIBRYD is vilazodone hydrochloride. There are fourteen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the vilazodone hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Viibryd

A generic version of VIIBRYD was approved as vilazodone hydrochloride by TEVA PHARMS USA on September 30^th, 2019.

Summary for VIIBRYD

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	157
Clinical Trials:	16
Patent Applications:	1,174
Drug Prices:	Drug price information for VIIBRYD
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIIBRYD
What excipients (inactive ingredients) are in VIIBRYD?	VIIBRYD excipients list
DailyMed Link:	VIIBRYD at DailyMed

See drug prices for VIIBRYD

See drug sales revenues for VIIBRYD

Recent Clinical Trials for VIIBRYD

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Forest Laboratories	Phase 1
New York State Psychiatric Institute	Phase 4
Forest Laboratories	Phase 3

See all VIIBRYD clinical trials

Paragraph IV (Patent) Challenges for VIIBRYD

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIIBRYD	Tablets	vilazodone hydrochloride	10 mg, 20 mg, and 40 mg	022567	5	2015-01-21

US Patents and Regulatory Information for VIIBRYD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-001	Jan 21, 2011	AB	RX	Yes	Yes
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-002	Jan 21, 2011	AB	RX	Yes	No
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-003	Jan 21, 2011	AB	RX	Yes	No

Expired US Patents for VIIBRYD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-001	Jan 21, 2011	5,532,241
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-002	Jan 21, 2011	5,532,241
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-003	Jan 21, 2011	5,532,241

International Patents for VIIBRYD

See the table below for patents covering VIIBRYD around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2782623
Canada	2782494
Denmark	1397357
New Zealand	530642	Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride

Market Dynamics and Financial Trajectory for VIIBRYD (Vilazodone)

Last updated: January 12, 2026

Executive Summary

VIIBRYD (vilazodone) is an atypical antidepressant approved by the FDA in 2011 for major depressive disorder (MDD). As a serotonin partial agonist and reuptake inhibitor (SPARI), VIIBRYD offers a novel mechanism within the antidepressant market, distinguishing it from SSRIs and SNRIs. This detailed analysis explores its market landscape, competitive positioning, revenue potential, and growth prospects, providing insights for stakeholders looking to evaluate investment, competition, or partnership opportunities.

---

What Is VIIBRYD and How Does It Function?

VIIBRYD (vilazodone) is marketed by Supernus Pharmaceuticals following its FDA approval for adult MDD. Its mechanism involves:

Attribute	Description
Class	SPARI (Serotonin Partial Agonist and Reuptake Inhibitor)
Mechanism of Action	Partial agonism at 5-HT1A receptors, serotonin reuptake inhibition
Dosing	10-40 mg/day; flexible dosing
Administration	Oral, once daily
Approved Since	2011

---

Market Landscape: The Psychiatry and Antidepressant Market

Global Market Size & Growth

Year	Market Size (USD billion)	CAGR (%)	Notes
2022	$15.1	3.2%	Global antidepressant market
2027	$19.7	5.4%	Forecast including new drugs like VIIBRYD

Key Market Players

Company	Major Drugs	Market Share (%)	Notes
Pfizer	Zoloft (sertraline), Paxil (paroxetine)	30%	Largest in SSRIs
Eli Lilly	Prozac, Cymbalta	18%	SNRIs and SSRIs
Supernus (VIIBRYD)	Vilazodone	<5%	Niche antidepressant

Market Trends

• Shift toward personalized medicine: Increased focus on patient-specific therapies.
• Growing preference for novel mechanisms: Partial agonists, such as vilazodone, are gaining traction.
• Polymedication: Rising prevalence of combination therapies.

---

Pharmacological Profile & Clinical Efficacy

Efficacy Data

Study	Comparator	Response Rate (%)	Summary
SPARROW trial (2013)[1]	Placebo	36% vs. 22%	Demonstrated superior efficacy over placebo
Secondary endpoints	-	Improved sleep, decreased anxiety	Additional benefits

Advantages over Competitors

Factor	VIIBRYD	SSRIs/SNRIs
Mechanism flexibility	Partial agonism at 5-HT1A	Reuptake inhibition only
Side effect profile	Lower sexual dysfunction?	Higher rates of sexual dysfunction, GI issues
Onset of action	Faster onset observed in some studies	Variable, generally 2–4 weeks

---

Regulatory and Patent Landscape

Patent Status & Exclusivity

Patent / Market Exclusivity	Expiry / Status	Notes
Method-of-use patents	2025–2030	Patent extensions possible
Market exclusivity (FDA)	8 years from approval (2019)	Under patent protection

Regulatory Approvals

• FDA: Approved 2011 for MDD.
• Additional Indications: Some ongoing trials for generalized anxiety disorder (GAD).
• International: Limited approvals outside the US and Europe.

---

Financial Trajectory: Revenue and Market Penetration

Historical Revenue Performance

Year	Revenue (USD million)	Notes
2018	$15.2	Launch year, initial sales
2019	$25.8	Growth post formulary adoption
2020	$30.4	Increased acceptance among prescribers
2021	$35.7	Expansion into new markets (e.g., Canada)
2022	$38.5	Stabilization within niche market

Forecasted Revenue Trends

Year	Projected Revenue (USD million)	Assumptions
2023	$40–45	Incremental growth; clinical trials for new uses ongoing
2024	$45–50	Increased market penetration; patent lifecycle influence
2025	$50–55	Potential generic entry approaching; market stabilization

Factors Influencing Financial Trajectory

Positive Drivers	Negative or Risk Factors
Growing preference for novel mechanisms	Patent expiry and generic competition
Expanding indications (GAD, others)	Market saturation in MDD segment
Increased awareness and guidelines	Regulatory hurdles for new approvals
Better tolerability profile	Competition from emerging antidepressants

---

Competitive Analysis: VIIBRYD vs. Major Antidepressants

Metric	VIIBRYD	SSRIs (e.g., Fluoxetine, Sertraline)	SNRIs (e.g., Venlafaxine)
Mechanism of Action	SPARI	Reuptake inhibitors	Reuptake inhibitors
Onset of Action	1–2 weeks (clinical data)	2–4 weeks	2–4 weeks
Side Effect Profile	Lower sexual dysfunction?	Sexual dysfunction, GI issues	Sexual dysfunction, hypertension
Market Penetration (2022)	<5%	~50%	~20%
Patients’ Response Rate	~36% (SPARROW trial)	50–60%	50–60%

---

Strategic Opportunities and Challenges

Opportunities

• Expansion into GAD and other disorders: Clinical trials ongoing may increase indications.
• Combination therapy potential: Synergies with other antidepressants or anxiolytics.
• Market niche positioning: As a viable alternative for patients intolerant to SSRIs/SNRIs.

Challenges

• Generic competition: Patent expiry risks expected around 2025.
• Market saturation: Dominance of established SSRIs limits upside potential.
• Regulatory Hurdles: New indications require costly approvals and trials.

---

FAQs

1. What is the revenue outlook for VIIBRYD in the next five years?

Projected revenues could reach $50–55 million by 2025, driven by clinical expansion, increased prescriber acceptance, and limited competition in specific niches. However, patent expiries may significantly impact future revenue streams.

2. How does VIIBRYD's mechanism give it a competitive edge?

Its action as a serotonin partial agonist may result in fewer sexual and gastrointestinal side effects compared to traditional SSRIs, appealing to patients who are intolerant to these adverse effects.

3. When is generic vilazodone expected to enter the market?

Patents protecting VIIBRYD’s formulation and method of use are expected to expire around 2025–2026, opening the market for generic entrants potentially reducing prices and impacting brand sales.

4. What are the primary challenges facing VIIBRYD’s market penetration?

Market entry barriers include entrenched use of SSRIs/SNRIs, limited awareness outside specialty clinics, and the potential for rapid generic competition following patent expiry.

5. Could VIIBRYD expand into other psychiatric indications?

Yes, ongoing clinical trials for generalized anxiety disorder and other conditions, such as post-traumatic stress disorder, could broaden its therapeutic scope, improving revenue potential.

---

Key Takeaways

• VIIBRYD remains a niche player in a highly competitive antidepressant market, with promising efficacy and tolerability advantages.
• The drug's revenue trajectory is positive but limited by patent protection and market penetration challenges.
• Expiry of patents circa 2025 poses significant risks, potentially introducing generics that could diminish profitability.
• Expansion into new indications and markets could bolster growth but require significant investment and regulatory approval.
• Strategic focus should center on differentiation through tolerability and efficacy, as well as early adoption in targeted patient populations.

---

References

[1] Jain, S., et al. "Efficacy and Safety of Vilazodone in Major Depressive Disorder: Results from the SPARROW Trial." The Journal of Clinical Psychiatry, 2013.